Valitor to Present at the Association for Research in Vision and Ophthalmology Annual Meeting
BERKELEY, Calif., March 23, 2023 (GLOBE NEWSWIRE) — Valitor, a biotechnology company engineering better medicines…
BERKELEY, Calif., March 23, 2023 (GLOBE NEWSWIRE) — Valitor, a biotechnology company engineering better medicines…
BERKELEY, Calif., March 23, 2023 (GLOBE NEWSWIRE) — Valitor, a biotechnology company engineering better medicines…
SEATTLE, March 23, 2023 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a…
SEATTLE, March 23, 2023 (GLOBE NEWSWIRE) — Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a…
March 24th presentation to highlight learnings related to pepinemab’s mechanism of action in both Huntington’s…
March 24th presentation to highlight learnings related to pepinemab’s mechanism of action in both Huntington’s…
Additional poster presentation to detail high-dose cohort safety data from Phase 2a trial of tegoprubart…
Additional poster presentation to detail high-dose cohort safety data from Phase 2a trial of tegoprubart…
LOS ANGELES, March 23, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc., a subsidiary of Immix Biopharma,…
LOS ANGELES, March 23, 2023 (GLOBE NEWSWIRE) — Nexcella, Inc., a subsidiary of Immix Biopharma,…
REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper),…
REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper),…
Media Release 2nd line NSCLC patients refractory to anti-PD-(L)1 treatment have few therapeutic options, and…
Media Release 2nd line NSCLC patients refractory to anti-PD-(L)1 treatment have few therapeutic options, and…
Oral Presentation to Feature Results from ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy…
Oral Presentation to Feature Results from ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy…
SEATTLE, March 23, 2023 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company…
SEATTLE, March 23, 2023 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company…
Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapy…
Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapy…